Springboard’s Health Innovation Hub is a collaboration platform advancing the growth of women-led digital health and life science companies with access to sources of funding, partnerships, and advisors. Learn more on their website, download the 1-pager, or apply here.
WP_Query Object
(
[query] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
)
[query_vars] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] => all
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
[order] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts
WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
ORDER BY RAND()
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 5065
[post_author] => 4
[post_date] => 2026-09-01 14:03:32
[post_date_gmt] => 2026-09-01 18:03:32
[post_content] =>
Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.
BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.
Application deadline: October 29, 2026, 5:00pm ET
For info sessions, eligibility and deadlines visit our REACH Website and FAQ.
The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.
Questions? Reach out to our program contacts or sign up for office hours:
Dee Dao, PhD, Associate Director, dee.dao@stonybrook.edu
Office Hours: Monday–Friday, 2–3:30 PM | Sign up Here
Zelda Mendelowitz, PhD, Venture Associate, zelda.mendelowitz@stonybrook.edu
Office Hours: Tuesday, Wednesday, Friday, 8–11 AM | Sign up Here
[post_title] => BioREACH: Translational Research Funding Opportunity
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => bioreach-translational-research-funding-opportunity
[to_ping] =>
[pinged] =>
[post_modified] => 2026-09-04 11:55:36
[post_modified_gmt] => 2026-09-04 15:55:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=5065
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 2708
[post_author] => 3
[post_date] => 2017-06-06 09:00:23
[post_date_gmt] => 2017-06-06 09:00:23
[post_content] => Innovative phase-0 proof-of-concept center continues advancement
of commercially promising biomedical innovations.
The Center for Biotechnology at Stony Brook University, on behalf of the Long Island Bioscience Hub (LIBH), announced the recipients of the fourth round of funded projects under the Hub’s technology development and commercialization initiative. Funding for five projects totaling $400,000 has been awarded to applicants from the Hub’s partner institutions. Partner institutions include Stony Brook University, Cold Spring Harbor Laboratory, Brookhaven National Laboratory, and the Feinstein Institute for Medical Research at Northwell Health. Over the last two years, more than $2.5M has been awarded to further the development of commercially promising technologies.
There are two categories of awards under the LIBH funding initiative – Feasibility and Proof-of-Concept. “Feasibility awards” are funded at up to $50,000 and designed to rapidly test the feasibility of new ideas in a “fail-fast-or-proceed” format, or to add value to existing intellectual property leading to new market applications. Proof-of-Concept awards provide up to $100,000 for targeted, milestone driven support for further development, testing, and analysis of existing intellectual property.
In this cycle, two feasibility awards have been given to Stony Brook University researchers exploring technologies that include a novel anti-fungal for life threatening blood infections and a new computational method for macrocyclic drug discovery. Proof-of-Concept projects this cycle include a drug-sensitive and drug-resistant TB combination therapy, a novel therapeutic for the treatment of colorectal cancer, and a next-generation medical imaging tool with applications in mammography.
“While the Long Island Bioscience Hub is only two‐years in existence, it has already had major impacts including the establishment of four companies.” said Clinton T. Rubin, Ph.D., Distinguished Professor, Chair, Department of Biomedical Engineering, and Director, Center for Biotechnology. “Additionally, this round of funding further enhances the LIBH-REACH pipeline that already has resulted in eight patent applications, five options/licenses and more than forty SBIR/STTR applications related to REACH technologies and small business clients.”
“I applaud the efforts of the Long Island Bioscience Hub as they continue to draw out the cutting edge biomedical innovations that exist within our research labs and their work with faculty innovators and the local bioscience community to accelerate commercial development.” said Dr. Richard Reeder, Vice President for Research at Stony Brook University. “Stony Brook University is deeply committed to the translation of basic research and the Hub’s successes demonstrate that we need to continue to foster the activities of the Hub.”
The technology development awards made available by the LIBH are specifically aimed at growing a pipeline of commercially promising biomedical technologies that can be out-licensed for further development or serve as the foundation for new company formations in the region. The main goal of the LIBH is to foster the development of therapeutics, preventatives, diagnostics, devices and research tools emerging from LIBH partner institutions that address diseases within the NIH’s mission.
Funded Projects –May 2017 Awards
“A Small Molecule Drug for the Treatment of Systemic Candidiasis” Nicolas Carpino, PhD and Jarrod French, Stony Brook University – Feasibility Award
“BRIKARD, a Program for Macrocyclic Drug Discovery” Evangelos Coutsias, PhD, Stony Brook University – Feasibility Award
“Selenium multi-Well Avalanche Detectors for Medical Imaging Applications” Amirhossein Goldan, PhD, Stony Brook University – Proof of Concept Award
“Developing Novel miR-129 Mimic Based Therapeutics for Colorectal Cancer” Jingfang Ju, PhD, Stony Brook University – Proof of Concept Award
“Azasteroid for Combination anti-TB Therapy” Nicole Sampson, PhD, Stony Brook University – Proof of Concept Award
Download a PDF of the press release here.
[post_title] => Long Island Bioscience Hub Announces Latest Funded Projects
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-bioscience-hub-announces-latest-funded-projects
[to_ping] =>
[pinged] =>
[post_modified] => 2017-06-05 14:55:40
[post_modified_gmt] => 2017-06-05 14:55:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2708
[menu_order] => 143
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 2552
[post_author] => 3
[post_date] => 2017-01-09 15:31:38
[post_date_gmt] => 2017-01-09 15:31:38
[post_content] => Sincerest congratulations to our clients who are being recognized among Stony Brook University's 40 under 40 for 2016. Since earning their Stony Brook degree, they have gone on to pursue their passions, help others and lead positive change.
J. Robert Coleman ’08, PhD Molecular Genetics and Microbiology - Chief Operating Officer, Codagenix, Inc
Katarzyna M. Sawicka ’04, ’05, ’14, BS Engineering Chemistry, MS Chemistry, PhD Biomedical Engineering - Founder and President, ImmunoMatrix
Joseph Scaduto ’08, MBA Business Administration - Founder and CEO, Traverse Biosciences Inc.
Additionally, warmest wishes of continued success to Stony Brook's Director of Government Relations, Lauren Brookmeyer, who was recently named a Long Island Business News "40 under 40 Class of 2017" honoree.
[post_title] => Congratulations 40 under 40 Winners!
[post_excerpt] => Three Center for Biotech clients are among the talented individuals recognized as Stony Brook University 's 2016 "40 under 40".
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => congratulations-40-under-40-winners
[to_ping] =>
[pinged] =>
[post_modified] => 2017-01-09 15:31:38
[post_modified_gmt] => 2017-01-09 15:31:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2552
[menu_order] => 155
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 4482
[post_author] => 4
[post_date] => 2024-09-16 10:10:47
[post_date_gmt] => 2024-09-16 14:10:47
[post_content] =>
CFB Client JelikaLite has been awarded a 2-year, $959,000 National Science Foundation (NSF) grant to develop a non-invasive therapeutic brain stimulation medical device to improve the communication, responsiveness, and social integration of autistic children.
JelikaLite is a clinical stage medical technology company developing a transformational neuromodulation platform for unmet needs in developmental pediatric disorders whose lead product is focused on Autism Spectrum Disorder (ASD).
The NSF project’s objectives are to finalize the current clinical prototype into a manufacturing-ready product and implement a platform for personalizing transcranial photobiomodulation (tPBM) treatment based on individual sensor -derived patient characteristics.
Details of the award can be found here.
[post_title] => CFB Client JelikaLite Awarded NSF Grant to Further Clinical Prototype
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => jelikalite-nsf24
[to_ping] =>
[pinged] =>
[post_modified] => 2025-02-24 12:44:30
[post_modified_gmt] => 2025-02-24 17:44:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4482
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 5065
[post_author] => 4
[post_date] => 2026-09-01 14:03:32
[post_date_gmt] => 2026-09-01 18:03:32
[post_content] =>
Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.
BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.
Application deadline: October 29, 2026, 5:00pm ET
For info sessions, eligibility and deadlines visit our REACH Website and FAQ.
The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.
Questions? Reach out to our program contacts or sign up for office hours:
Dee Dao, PhD, Associate Director, dee.dao@stonybrook.edu
Office Hours: Monday–Friday, 2–3:30 PM | Sign up Here
Zelda Mendelowitz, PhD, Venture Associate, zelda.mendelowitz@stonybrook.edu
Office Hours: Tuesday, Wednesday, Friday, 8–11 AM | Sign up Here
[post_title] => BioREACH: Translational Research Funding Opportunity
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => bioreach-translational-research-funding-opportunity
[to_ping] =>
[pinged] =>
[post_modified] => 2026-09-04 11:55:36
[post_modified_gmt] => 2026-09-04 15:55:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=5065
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 285
[max_num_pages] => 95
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] =>
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] => 1
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] =>
[query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
[query_cache_key:WP_Query:private] =>
)